ThoroughCare | $5,000,000 | (Nov 20, 2024)
OneChronos | $32,000,000 | (Nov 20, 2024)
EarthOptics | $24,000,000 | (Nov 20, 2024)
PlateletBio
United States
- Watertown, Massachusetts
- 04/11/2021
- Series B
- $75,500,000
PlateletBio is the only allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a completely new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a superior cell therapy empowered to tackle previously unmet medical challenges.
- Industry Biotechnology Research
- Website https://www.plateletbio.com/
- LinkedIn https://www.linkedin.com/company/platelet-biogenesis/about/
Related People
Sam RastyFounder
United States -
Greater Boston
Biotech CEO with 25+ years of experience in leadership roles of increasing responsibility spanning global large pharma, mid-cap pharma and small, private biotech. Success in start-up company formation and launch, strategy formulation, fund raising, operations, R&D, manufacturing, corporate development, BD&L and M&A. Strategic and operational leader with product development experience in multiple therapeutic areas and technology platforms spanning small molecules to biologics to more complex gene and cell therapies.
Citizen Health | $14,500,000 | (Nov 20, 2024)
Kong Inc. | $175,000,000 | (Nov 20, 2024)
RIIG | $3,000,000 | (Nov 20, 2024)
Tokamak Energy | $12,000,000 | (Nov 20, 2024)
Taito.ai | $2,700,000 | (Nov 20, 2024)
OSYTE [O-Sight] | $4,000,000 | (Nov 20, 2024)
Levanta | $20,000,000 | (Nov 20, 2024)
Jimini Health | $8,000,000 | (Nov 20, 2024)
Kalder | $10,500,000 | (Nov 20, 2024)
Lightsynq | $18,000,000 | (Nov 20, 2024)